ORIC Pharmaceuticals Q3 EPS $(0.44) Beats $(0.46) Estimate
Portfolio Pulse from Benzinga Newsdesk
ORIC Pharmaceuticals reported Q3 losses of $(0.44) per share, beating the analyst consensus estimate of $(0.46) by 4.35 percent. This represents a 12 percent improvement over losses of $(0.50) per share from the same period last year.
November 06, 2023 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ORIC Pharmaceuticals reported better than expected Q3 earnings, with losses per share improving by 12% YoY.
ORIC Pharmaceuticals reported a smaller loss than expected for Q3, beating analyst estimates. This is generally seen as a positive sign and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100